Rigel Pharmaceuticals
RIGL
121 hedge funds and large institutions have $316M invested in Rigel Pharmaceuticals in 2016 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 43 increasing their positions, 42 reducing their positions, and 18 closing their positions.
186% more call options, than puts
Call options by funds: $3.05M | Put options by funds: $1.07M
69% more capital invested
Capital invested by funds: $187M → $316M (+$129M)
6% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 18
2% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 42
1% more funds holding
Funds holding: 120 → 121 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$6.86M |
| 2 |
Goldman Sachs
New York
|
+$4.75M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$3.31M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$2.19M |
| 5 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$2.08M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$5.2M |
| 2 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$4.32M |
| 3 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$2.14M |
| 4 |
NI
Numeric Investors
Boston,
Massachusetts
|
-$1.89M |
| 5 |
SAM
Senzar Asset Management
New York
|
-$1.54M |
RIGL Hedge Fund Activity: Q3 2016 in Review
121 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q3 2016, worth a combined $316M — up 69% from $187M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new RIGL positions and 18 closed out — a net gain of 1 holder — while 43 added to existing stakes and 42 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $6.86M. The largest seller was Deerfield Management, exiting entirely with an estimated $5.2M sold.
- 121 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q3 2016, up from 120 in Q2 2016.
- Funds reported $316M of Rigel Pharmaceuticals stock for Q3 2016, up 69% quarter-over-quarter.
- 19 funds opened new Rigel Pharmaceuticals positions in Q3 2016 and 18 closed out, a net change of +1 holder.
- The largest Rigel Pharmaceuticals buyer in Q3 2016 was Citadel Advisors, an estimated $6.86M added.
- The largest Rigel Pharmaceuticals seller in Q3 2016 was Deerfield Management, an estimated $5.2M sold.
Based on aggregated 13F filings for Q3 2016.